Enveric Biosciences licenses its EB-002 drug candidate to MycoMedica Life Sciences, focusing on mental health treatment advancements. Enveric receives up to $62M in milestone payments and royalties, ...
Enveric Biosciences (ENVB) announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-licensing the Company’s EVM201 program, including drug candidate EB-002.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule ...
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Life Itself Conference – MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and ...
CAMBRIDGE, Mass. - Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology company specializing in the development of treatments for mental health disorders, has entered into a licensing agreement ...
Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass. — Enveric Biosciences, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results